INDICATION

Aptensio XR® (methylphenidate HCl extended-release) is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

For US Healthcare Professionals

IMPORTANT SAFETY INFORMATION

WARNING: ABUSE AND DEPENDENCE

CNS stimulants, including Aptensio XR, other methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.

.

RANGE OF DOSES

Once-daily Aptensio XR comes in 7 dosage strengths for individualized treatment1

.

The range of doses with Aptensio XR helps you address each patient’s needs

Capsules Capsules

There is no generic substitute for Aptensio XR.

Initiating treatment

  • The recommended starting dose of Aptensio XR® (methylphenidate HCl extended-release) for patients 6 years and older is 10 mg once daily in the morning with or without food1
    • Advise patients to establish a routine pattern with regard to meals. The dose should be individualized according to the needs and response of the patient1
  • The dose may be increased weekly in increments of 10 mg. Daily doses above 60 mg have not been studied and are not recommended1
Capsules are not shown at actual size.

Evaluating treatment

  • Pharmacological treatment of ADHD may be needed for extended periods. Periodically reevaluate the long‐term use of Aptensio XR, and adjust the dosage as needed1

Reducing or discontinuing treatment

  • If paradoxical aggravation of symptoms or other adverse reactions occur, the dosage should be reduced, or, if necessary, the drug should be discontinued1
  • If improvement is not observed after appropriate dosage adjustment over a 1‐month period, the drug should be discontinued1
.

IMPORTANT SAFETY INFORMATION

WARNING: ABUSE AND DEPENDENCE

CNS stimulants, including Aptensio XR, other methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.